- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04990596
Mechanisms fo Clopidogrel Resistance in Older Adults (CEPAGE) (CEPAGE)
November 24, 2023 updated by: Rennes University Hospital
Mechanisms fo Clopidogrel Resistance in Older Adults
A clopidogrel resistance rate of 40-50% has been found in the population over 70 years of age, whereas biological resistance, associated with an increased risk of cardiovascular events, is observed in about 20-30% of younger patients.
One hypothesis is that the active metabolite is less available in resistant patients.
Indeed, 85% of the absorbed clopidogrel undergoes inactivation by esterases.
Then the remaining fraction undergoes two steps of metabolisation to the active thiol metabolite by CYP450, essentially the isoform 2C19.
In older adults, increased esterase activity and/or decreased CYP450 2C19 activity may lead to a decreased concentration of the active metabolite.
Multiple chronic conditions and polypharmacy encountered in older individuals are associated with basal platelet hyperactivity, and may also contribute to a poor response to clopidogrel.
No data on the relationship between platelet response and circulating metabolite levels, or on the determinants of response to clopidogrel, are currently available in the geriatric population.
Therefore, we propose to analyse the relationship between age and platelet and extra-platelet mechanisms potentially involved in the variability of response to clopidogrel.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This study is a prospective observational multi-centre study.
The main objective is assessing the pharmacokinetics (PK) and pharmacodynamics (PD) correlation of clopidogrel action in older adults, i.e. correlation between clopidogrel active metabolite concentration (PK) and platelet response phenotype (PD).
The primary outcome is the correlation between the concentration of active metabolite of clopidogrel (PK) over the percentage of maximum aggregation at 10 μM ADP (PD) as a function of age.
Inclusion criteria are: age 50-100 years old, hospitalization in one of the 4 participating centres, treatment with clopidogrel 75 milligrammes per day, for at least 10 days.
The statistical analysis is a multiple linear regression model with the introduction of an interaction term.
The first variable of interest (explanatory) is the concentration of the metabolite.
A linear regression model will be used to estimate the proportion of variance explained.
The analyses will be conducted with SAS version 9.4 (SAS Institute Inc., Cary, N.C., USA).
Results will be published in an international scientific review.
Study Type
Observational
Enrollment (Estimated)
100
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Joaquim PRUD'HOMM, MD
- Phone Number: +33 2 99 28 41 10
- Email: joaquim.prud'homm@chu-rennes.fr
Study Contact Backup
- Name: Isabelle GOUIN-THIBAULT, MD, PhD
- Phone Number: +33 2 99 28 95 63
- Email: isabelle.gouin@chu-rennes.fr
Study Locations
-
-
-
Paris, France
- Not yet recruiting
- Hôpital Charles Foix
-
Contact:
- Eric PAUTAS, Pr
-
Paris, France
- Recruiting
- Hôpital Européen Georges Pompidou,
-
Contact:
- Elena PAILLAUD, MD
-
Paris, France
- Recruiting
- Hopital Lariboisiere
-
Contact:
- Jean-Guillaume DILLINGER, MD
-
Rennes, France
- Recruiting
- CHU de Rennes
-
Contact:
- Dominique SOMME, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years to 100 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
patients from 50 to 100 years treated with clopidogrel 75 mg/d for at least 10 days for primary or secondary prevention of cardiovascular events
Description
Inclusion Criteria:
Consecutive patients per 10-year age range, (20 patients per age range from 50 to 100 years included) :
- in consultation or hospitalization in one of the participating centres,
- treatment with clopidogrel 75 mg/d for at least 10 days for primary or secondary prevention of cardiovascular events.
- who have received the information and have not expressed their opposition to participate in the study and who have given their written consent for the performance of genetic examinations and the realization of a biocollection
- affiliated to French social security system
Exclusion criteria :
- treatment with another antithrombotic agent,
- myeloproliferative syndrome,
- platelet count < 100 G/L,
- acute inflammatory situation: severe sepsis, documented acute infection, chronic systemic inflammatory disease or active cancer,
- under dialysis,
- no participation in another clinical study,
- deprived of liberty
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Age Group 50 to 59
Inclusion criteria :
Non-inclusion criteria :
|
One sample per patient will be taken 1 to 3 hours after clopidogrel administration.
Four additional tubes of 3 mL each will be collected for the study, for a total volume of 12 mL.
|
Age Group 60 to 69
Inclusion criteria :
Non-inclusion criteria :
|
One sample per patient will be taken 1 to 3 hours after clopidogrel administration.
Four additional tubes of 3 mL each will be collected for the study, for a total volume of 12 mL.
|
Age Group 70 to 79
Inclusion criteria :
Non-inclusion criteria :
|
One sample per patient will be taken 1 to 3 hours after clopidogrel administration.
Four additional tubes of 3 mL each will be collected for the study, for a total volume of 12 mL.
|
Age Group 80 to 89
Inclusion criteria :
Non-inclusion criteria :
|
One sample per patient will be taken 1 to 3 hours after clopidogrel administration.
Four additional tubes of 3 mL each will be collected for the study, for a total volume of 12 mL.
|
Age Group 90 to 100
Inclusion criteria :
Non-inclusion criteria :
|
One sample per patient will be taken 1 to 3 hours after clopidogrel administration.
Four additional tubes of 3 mL each will be collected for the study, for a total volume of 12 mL.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PK/PD correlation - clopidogrel active metabolite concentration (pharmacokinetics PK in ) / platelet response phenotype(pharmacodynamics, PD)
Time Frame: Day 0
|
Correlation PK (concentration of active metabolite of clopidogrel) / PD (%maximum aggregation at 10 μM ADP) as a function of age
|
Day 0
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Correlation of prodrug/active metabolite concentrations
Time Frame: Day 0
|
Ratio of prodrug/active metabolite concentrations as a function of age
|
Day 0
|
Correlation between the area under the curve of aggregationat 10 μM ADP and the concentration of the active metabolite of clopidogrel
Time Frame: Day 0
|
Correlation between the area under the curve of aggregation at 10μM ADP and the concentration of the active metabolite of clopidogrelas a function of age
|
Day 0
|
Correlation between the Platelet Reactivity Index of VASPphosphorylation and the concentration of the active metabolite of clopidogrel
Time Frame: Day 0
|
Correlation between the Platelet Reactivity Index of VASP phosphorylation and the concentration of the active metabolite of clopidogrel in relation to age
|
Day 0
|
Determination of factors influencing PK/PD response
Time Frame: Day 0
|
clinical data: gender
|
Day 0
|
Determination of factors influencing PK/PD response
Time Frame: Day 0
|
clinical data: body mass index in kg/m^2
|
Day 0
|
Determination of factors influencing PK/PD response
Time Frame: Day 0
|
clinical data: Cumulative Illness Rating Scale-Geriatric
|
Day 0
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Dominique SOMME, MD, Pr, CHU de Rennes - Service de Gériatrie
- Principal Investigator: Isabelle GOUIN-THIBAULT, MD, PhD, CHU de Rennes - Service d'Hématologie Biologique
- Principal Investigator: Eric PAUTAS, MD, Pr, Hôpital Charles Foix - Court séjour Gériatrique
- Principal Investigator: Corinne FRERE, MD, CHU Pitié-Salpêtrière - Hématologie Biologique
- Principal Investigator: Elena PAILLAUD, MD, Hôpital Européen Georges Pompidou, Service de Gériatrie Aiguë,
- Principal Investigator: Pascale GAUSSEM, MD, Pr, Hôpital Européen Georges Pompidou - Service d'Hématologie Biologique,
- Principal Investigator: Jean-Guillaume DILLINGER, MD, Hôpital Lariboisière - Service de Cardiologie
- Principal Investigator: Virginie SIGURET, MD, Pr, Hôpital Lariboisière - Hématologie Biologique
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 12, 2021
Primary Completion (Estimated)
July 12, 2025
Study Completion (Estimated)
January 12, 2026
Study Registration Dates
First Submitted
May 6, 2021
First Submitted That Met QC Criteria
July 26, 2021
First Posted (Actual)
August 4, 2021
Study Record Updates
Last Update Posted (Actual)
November 27, 2023
Last Update Submitted That Met QC Criteria
November 24, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 35RC19_9831_CEPAGE
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Drug Resistance
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...RecruitingIncreased Drug Resistance | Resistance Bacterial | Drug Resistance, MicrobialBangladesh
-
Human Biome Institute S.A.RecruitingAntimicrobial Drug Resistance | Drug Resistance, BacterialPoland
-
University of AarhusDanish Research AgencyCompleted
-
University Hospital, Basel, SwitzerlandCompleted
-
National Institute of Mental Health (NIMH)Completed
-
Medstar Health Research InstituteUnknownIncreased Drug ResistanceUnited States
-
University Hospital, AkershusOslo University Hospital; Helse Stavanger HF; Sorlandet Hospital HF; Sykehuset... and other collaboratorsTerminatedAntibiotic Drug Resistance
-
Centre Hospitalier Universitaire de BesanconCompletedDrug Resistance, BacterialFrance
-
Tourcoing HospitalRecruitingDrug Resistance, Multiple, BacterialFrance
-
Christoph HatzUniversity of ZurichCompletedDrug Resistance, Multiple | Travel MedicineSwitzerland
Clinical Trials on additional blood sample
-
Centre Hospitalier Universitaire de NiceCompleted
-
Centre Hospitalier Universitaire de BesanconCompleted
-
Centre Hospitalier Universitaire de BesanconUnknown
-
Centre Hospitalier Universitaire de BesanconCompleted
-
Centre Hospitalier Universitaire de BesanconCompletedAvian Hypersensitivity PneumonitisFrance
-
Hospices Civils de LyonRecruitingFamilial Mediterranean Fever | MEFV Gene MutationFrance
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingCerebral Small Vessel Diseases | CADASIL (Diagnosis)
-
Centre Hospitalier Universitaire DijonUnknownObesity | Overweight | Type 2 DiabetesFrance
-
Centre Hospitalier Universitaire de BesanconCompleted
-
Centre Hospitalier Universitaire de BesanconUnknown